Translational Approaches to Develop Drug Therapy for Diarrhea

开发腹泻药物治疗的转化方法

基本信息

  • 批准号:
    9892562
  • 负责人:
  • 金额:
    $ 7.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-04-01 至 2021-06-30
  • 项目状态:
    已结题

项目摘要

Acute and chronic diarrheal diseases are major contributors to mortality and morbidity in developing countries where they are the second most frequent cause of infant mortality and to morbidity in the USA where they represent a huge economic burden. Lacking approved, safe and highly effective anti-diarrheal drugs, a NIH Single Topic Conference held 9/2011 concluded that development of drug therapy to treat all forms of diarrhea has a high research priority with the goal of reducing the duration and amount of diarrhea. The needed information that was lacking for diarrheal drug development was not felt to be in our understanding of the pathophysiology of diarrhea as due to inhibition of Na+ absorption with or without stimulation of Cl- secretion. Rather it was lack of information about the distribution and extent of expression of major ion transport proteins in the normal human intestine, how this changes with age, and how transporter activity and expression changes with various diarrheas. This R24 represents a collaborative effort of 5 principle investigators from three institutions all of whom have a primary research interest in intestinal epithelial transport and its regulation, but who bring expertise in several different but complementary areas of research which are needed to address the aims of this project. In this way we propose to provide the scientific underpinning needed for current and future development of anti-diarrheal drugs. The Aims of this project are to I. Develop a catalogue of the intestinal expression of potential anti-diarrheal drug targets in healthy controls and diarrheas using archived human intestine, mouse intestine and human enteroids; standardize model diarrheas in mouse small intestine and human enteroids; and perform a phenotypic screen using human enteroids to identify unique drugs to treat the diarrhea models. II. Determine changes in function of specific Na+ absorptive and Cl- secretory transporters in the diarrhea models and the mechanisms by which they occur, including effects of the newly identified anti-diarrheal drugs. III. Determine the efficacy of novel anti-secretory and pro-absorptive therapeutics in in vivo and ex vivo diarrheal models. High throughput screen for NHE3 stimulators.
急慢性腹泻病是#年死亡率和发病率的主要因素。 在发展中国家,它们是婴儿死亡的第二大原因, 到美国的发病率,在那里他们代表着巨大的经济负担。缺乏批准, 安全高效的止泻药,美国国立卫生研究院2011年9月举行的单一主题会议 结论是药物疗法的发展对治疗各种形式的腹泻都有很高的 优先研究,目标是减少腹泻的持续时间和数量。所需的 缺乏腹泻药物开发的信息在我们的 对Na+吸收受抑所致腹泻的病理生理学认识 或无氯离子分泌刺激。相反,这是因为缺乏关于 主要离子转运蛋白在正常人体内的分布和表达程度 肠道,这种变化如何随着年龄的变化,以及转运蛋白的活动和表达如何变化 伴随着各种腹泻。R24代表了5个主要调查人员的协作努力 来自三个机构,他们都对肠道上皮细胞有主要的研究兴趣 运输及其监管,但谁带来了几个不同但互补的专业知识 为实现该项目的目标所需的研究领域。通过这种方式,我们 建议为当前和未来的发展提供所需的科学基础 止泻药。这个项目的目的是为了。开发一个肠道的目录。 潜在的止泻药物靶点在健康对照和腹泻患者中的表达 存档的人体肠道、小鼠肠道和人体肠类;标准化模型 小鼠小肠和人类肠道的腹泻;并进行表型筛选 使用人类肠样来识别治疗腹泻模型的独特药物。二、确定 腹泻时特异性钠离子吸收转运体和氯离子分泌转运体功能的变化 模型及其发生机制,包括新确定的 止泻药。三、测定新型抗分泌剂和促吸收药的疗效 体内和体外腹泻模型的治疗。适用于NHE3的高通量屏幕 刺激器。

项目成果

期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A Novel Peptide Prevents Enterotoxin- and Inflammation-Induced Intestinal Fluid Secretion by Stimulating Sodium-Hydrogen Exchanger 3 Activity.
一种新型肽通过刺激钠氢交换器 3 活性来防止肠毒素和炎症引起的肠液分泌。
  • DOI:
    10.1053/j.gastro.2023.06.028
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    29.4
  • 作者:
    Zachos,NicholasC;Vaughan,Hannah;Sarker,Rafiquel;Est-Witte,Savannah;Chakraborty,Molee;Baetz,NicholasW;Yu,Hongzhe;Yarov-Yarovoy,Vladimir;McNamara,George;Green,JordanJ;Tse,Chung-Ming;Donowitz,Mark
  • 通讯作者:
    Donowitz,Mark
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARK DONOWITZ其他文献

MARK DONOWITZ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARK DONOWITZ', 18)}}的其他基金

Mechanisms and Correction of Abnormal Bicarbonate Secretion by DRA in Diarrhea
DRA 治疗腹泻时碳酸氢盐异常分泌的机制及纠正
  • 批准号:
    9753444
  • 财政年份:
    2019
  • 资助金额:
    $ 7.97万
  • 项目类别:
Mechanisms and Correction of Abnormal Bicarbonate Secretion by DRA in Diarrhea
DRA 治疗腹泻时碳酸氢盐异常分泌的机制及纠正
  • 批准号:
    9981963
  • 财政年份:
    2019
  • 资助金额:
    $ 7.97万
  • 项目类别:
Pathogenesis of E. coli and Shigella infections in human enteroid models
人肠模型中大肠杆菌和志贺氏菌感染的发病机制
  • 批准号:
    10190298
  • 财政年份:
    2016
  • 资助金额:
    $ 7.97万
  • 项目类别:
Pathogenesis of E. coli and Shigella infections in human enteroid models
人肠模型中大肠杆菌和志贺氏菌感染的发病机制
  • 批准号:
    9982173
  • 财政年份:
    2016
  • 资助金额:
    $ 7.97万
  • 项目类别:
Pathogenesis of E. coli and Shigella infections in human enteroid models
人肠模型中大肠杆菌和志贺氏菌感染的发病机制
  • 批准号:
    10745560
  • 财政年份:
    2016
  • 资助金额:
    $ 7.97万
  • 项目类别:
Pathogenesis of E. coli and Shigella infections in human enteroid models
人肠模型中大肠杆菌和志贺氏菌感染的发病机制
  • 批准号:
    10427388
  • 财政年份:
    2016
  • 资助金额:
    $ 7.97万
  • 项目类别:
Translational Approaches to Develop Drug Therapy for Diarrhea
开发腹泻药物治疗的转化方法
  • 批准号:
    9298626
  • 财政年份:
    2014
  • 资助金额:
    $ 7.97万
  • 项目类别:
Translational Approaches to Develop Drug Therapy for Diarrhea
开发腹泻药物治疗的转化方法
  • 批准号:
    8769280
  • 财政年份:
    2014
  • 资助金额:
    $ 7.97万
  • 项目类别:
Human Intestinal Organoids: Pre-Clinical Models of Non-Inflammatory Diarrhea
人类肠道类器官:非炎症性腹泻的临床前模型
  • 批准号:
    8668192
  • 财政年份:
    2012
  • 资助金额:
    $ 7.97万
  • 项目类别:
Human Intestinal Organoids: Pre-Clinical Models of Non-Inflammatory Diarrhea
人类肠道类器官:非炎症性腹泻的临床前模型
  • 批准号:
    8516141
  • 财政年份:
    2012
  • 资助金额:
    $ 7.97万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 7.97万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.97万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 7.97万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.97万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 7.97万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 7.97万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.97万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 7.97万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 7.97万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.97万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了